{"id":9318,"date":"2015-03-28T08:37:13","date_gmt":"2015-03-28T07:37:13","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=9318"},"modified":"2015-03-28T10:41:07","modified_gmt":"2015-03-28T09:41:07","slug":"farmaci-blockbuster-11-nuovi-arrivi-previsti-entro-un-anno","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-blockbuster-11-nuovi-arrivi-previsti-entro-un-anno\/","title":{"rendered":"Blockbuster drugs, 11 new arrivals expected within a year"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/mms.businesswire.com\/media\/20141222006081\/en\/443112\/5\/Opdivo_1.jpg\" alt=\"\" width=\"358\" height=\"239\" \/>Over the next twelve months, numerous drugs destined for great commercial success will enter the pharmaceutical market: there will be exactly eleven, according to the Thomson Reuters news agency. Experts have compiled a ranking in which the first place is occupied by <strong>nivolumab<\/strong>, Bristol-Myers Squibb&#039;s drug for the intravenous treatment of melanoma, which is expected to reach sales of $5.7 billion by 2019. Nivolumab is a Pd-1 immune checkpoint inhibitor antibody and has shown a response rate of 32% in a randomized phase 3 study in patients with unresectable or metastatic melanoma, in whom first-line treatment failed to arrest disease progression.<\/p>\n<p>Approved last December by the FDA, it is currently under review by the EMA. Taking second place in the ranking is alirocumab, developed by Sanofi and Regeneron: it is a monoclonal antibody targeted against the Pcsk9 protein, a substance produced by the liver that interferes with LDL cholesterol receptors. For alirocumab, Thomson Reuters forecasts 4.4 billion in sales, also by 2019.<\/p>\n<p>In third place is a therapeutic combination from Novartis indicated for the treatment of chronic heart failure: the drug contains sacubitril (a neprilysin inhibitor) and valsartan (angiotensin receptor antagonist) and appears destined to reach a turnover of 3, 7 billion dollars. The other eight drugs in the rankings are: the experimental anticancer palbociclib; the combination of ivacaftor and lumacaftor for patients with cystic fibrosis; the combined regimen of the antiviral agents veruprevir, ritonavir, ombitasvir and dasabuvir for the treatment of hepatitis C; evolocumab, a principle belonging to the new class of Pcsk9 anti-cholesterol drugs; Gardasil 9 for the prevention of tumors caused by papilloma viruses; brexpiprazole, to treat schizophrenia, depression and agitation states in patients with Alzheimer&#039;s disease; toujeo, a new formulation of insulin glargine and finally Secukinumab, a first-line systemic treatment of psoriasis.<\/p>\n<p><a href=\"http:\/\/www.farmacista33.it\/farmaci-blockbuster-nuovi-arrivi-previsti-entro-un-anno\/pianeta-farmaco\/news--30972.html?xrtd=TYAXTXLRCATXRCPTXCXRASV\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Renato Torlaschi \u2013 Saturday, 28 March 2015 \u2013 Pharmacist33<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nei prossimi dodici mesi entreranno sul mercato farmaceutico numerosi farmaci destinati a un grande successo commerciale: saranno esattamente undici, secondo l&#8217;agenzia di stampa Thomson Reuters. Gli esperti hanno stilato una classifica in cui il primo posto \u00e8 occupato dal nivolumab, farmaco di Bristol-Myers Squibb per il trattamento endovenoso del melanoma, che secondo le previsioni \u00e8 &hellip;<\/p>","protected":false},"author":4,"featured_media":9321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[26],"class_list":["post-9318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=9318"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9321"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=9318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=9318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=9318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}